검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | NK immunotherapy |
Overview Company | Beijing Biotech |
Overview Modality | ANTIBODY |
Overview Target | Recurrent Pharyngeal Cancer |
Overview Indication | Recurrent Ovarian Cancer |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | target/off-tumour toxicity, resistance to dominant suppressive pathway |
MoA Biomarker | HER2-positive |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Construction of anti-HER2 affibody-directed CAR-NK and its synergistic effects with doxorubicin-loaded nanodrug against HER2-positive breast cancer.. Chimeric antigen receptor (CAR)-engineered T or natural killer (NK) cells are a promising approach for cancer immunotherapy. The leading region of the CAR structure is generally a single-chain antibody (scFv) fragment specific for a tumor cell surfac… |
Toxicology CRS | Reported |
Clinical ORR | 0% |
Clinical Result source | ClinicalTrials.gov NCT02099539 |
Clinical Data Tier / Score | A · 31 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | NK immunotherapy |
Overview Company | Beijing Biotech |
Overview Modality | ANTIBODY |
Overview Target | Recurrent Pharyngeal Cancer |
Overview Indication | Recurrent Ovarian Cancer |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | target/off-tumour toxicity, resistance to dominant suppressive pathway |
MoA Biomarker | HER2-positive |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Construction of anti-HER2 affibody-directed CAR-NK and its synergistic effects with doxorubicin-loaded nanodrug against HER2-positive breast cancer.. Chimeric antigen receptor (CAR)-engineered T or natural killer (NK) cells are a promising approach for cancer immunotherapy. The leading region of the CAR structure is generally a single-chain antibody (scFv) fragment specific for a tumor cell surfac… |
Toxicology CRS | Reported |
Clinical ORR | 0% |
Clinical Result source | ClinicalTrials.gov NCT02099539 |
Clinical Data Tier / Score | A · 31 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
추천 비교
추천 비교